Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023

About this update from Kiniksa Pharmaceuticals International, Plc

[{"type":"text","content":"HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a.m. Eastern Time to report its first quarter 2023 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please www.kiniksa.com. ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. Every Second Counts! ®Kiniksa Investor and Media ContactRachel Frank(339) [email protected] \nSource: Kiniksa Pharmaceuticals, Ltd.","length":3581,"tagName":"div"}]

More updates from Kiniksa Pharmaceuticals International, Plc